Skip to main content
SpringerLink
Log in

Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer

  • Letter to the Editor
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53(3):354–61 (Epub 2017/11/16).

    Article  PubMed  Google Scholar 

  2. Antonio P, Natale F. Gastric cancer prevention and Helicobacter pylori. J Gastroenterol. 2018 (in press).

  3. Hirayama Y, Kawai T, Otaki J, Kawakami K, Harada Y. Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J Gastroenterol Hepatol. 2014;29(Suppl 4):16–9.

    Article  PubMed  Google Scholar 

  4. Martini S, D’Addario C, Braconi D, Bernardini G, Salvini L, Bonechi C, et al. Antibacterial activity of grape extracts on cagA-positive and -negative Helicobacter pylori clinical isolates. J Chemother. 2009;21(5):507–13 (Epub 2009/11/26).

    Article  PubMed  CAS  Google Scholar 

  5. Parente F, Imbesi V, Cucino C, MacOni G, Russo U, Duca PG, et al. Helicobacter pylori CagA seropositivity does not influence inflammatory parameters, lipid concentrations and haemostatic factors in healthy individuals. J Intern Med. 2000;247(2):213–7 (Epub 2000/02/26).

    Article  PubMed  CAS  Google Scholar 

  6. Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol. 2004;39(2):97–103 (Epub 2004/04/08).

    Article  PubMed  CAS  Google Scholar 

  7. Suzuki H, Mori H. Different pathophysiology of gastritis between east and west? An Asian perspective. Inflamm Intest Dis. 2016;1(3):123–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5). (Epub 2017/08/05).

  9. Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, et al. Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host Microbe. 2012;12(6):764–77 (Epub 2012/12/19).

    Article  PubMed  CAS  Google Scholar 

  10. Fan X, Long A, Goggins M, Fan X, Keeling PW, Kelleher D. Expression of CD44 and its variants on gastric epithelial cells of patients with Helicobacter pylori colonisation. Gut. 1996;38(4):507–12 (Epub 1996/04/01).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46 (Epub 2016/03/05).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, et al. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for helicobacter pylori strains containing the gyrA mutation. Helicobacter. 2016;21(4):286–94 (Epub 2015/11/28).

    Article  PubMed  CAS  Google Scholar 

  13. Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients. United Eur Gastroenterol J. 2017;5:796–804 (2050640616688995).

    Article  CAS  Google Scholar 

  14. Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, et al. Rifabutin-based 10- and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United Eur Gastroenterol J. 2016;4(3):380–7 (Epub 2016/07/13).

    Article  CAS  Google Scholar 

  15. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009;53(4):1720–1 (Epub 2009/02/04).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Suzuki H, Mori H. Helicobacter pylori: Helicobacter pylori gastritis-a novel distinct disease entity. Nat Rev Gastroenterol Hepatol. 2015;12(10):556–7 (Epub 2015/09/16).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

    Hideki Mori

  2. Fellowship Training Center and Medical Education Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Hidekazu Suzuki

Authors
  1. Hideki Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hidekazu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidekazu Suzuki.

Additional information

This reply refers to the comment available at: https://doi.org/10.1007/s00535-018-1453-3.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mori, H., Suzuki, H. Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer. J Gastroenterol 53, 789–790 (2018). https://doi.org/10.1007/s00535-018-1454-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-018-1454-2

Search

Navigation